[go: up one dir, main page]

CU23630A1 - Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae - Google Patents

Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae

Info

Publication number
CU23630A1
CU23630A1 CU20060207A CU20060207A CU23630A1 CU 23630 A1 CU23630 A1 CU 23630A1 CU 20060207 A CU20060207 A CU 20060207A CU 20060207 A CU20060207 A CU 20060207A CU 23630 A1 CU23630 A1 CU 23630A1
Authority
CU
Cuba
Prior art keywords
flaviviridae family
chemeric
properties against
peptide molecules
against viruses
Prior art date
Application number
CU20060207A
Other languages
English (en)
Inventor
Santiago Glay Chinea
Nunez Monica Sarria
Mayora Patricia Grabiela Toledo
Cruz Osmany Guirola
Salazar Noralvis Fleitas
Dunn Alejandro Miguel Martin
Galindo Vivian Huerta
Lasa Alexis Musacchio
Rico Ania Cabrales
Perez Hilda Elisa Garay
Acosta Osvaldo Reyes
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20060207A priority Critical patent/CU23630A1/es
Priority to KR1020097010930A priority patent/KR101449494B1/ko
Priority to RU2009120596/10A priority patent/RU2451026C2/ru
Priority to CN2007800466743A priority patent/CN101588818B/zh
Priority to US12/513,085 priority patent/US8674063B2/en
Priority to CA2668045A priority patent/CA2668045C/en
Priority to ES07817384T priority patent/ES2392106T3/es
Priority to AU2007315485A priority patent/AU2007315485A1/en
Priority to PCT/CU2007/000020 priority patent/WO2008052490A2/es
Priority to EP07817384A priority patent/EP2085098B1/en
Priority to MX2009004761A priority patent/MX2009004761A/es
Priority to JP2009534979A priority patent/JP5253405B2/ja
Priority to ARP070104814A priority patent/AR063725A1/es
Priority to BRPI0718097-7A priority patent/BRPI0718097A2/pt
Priority to ZA200903318A priority patent/ZA200903318B/xx
Publication of CU23630A1 publication Critical patent/CU23630A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención está relacionada con péptidos quiméricos, cuya estructura primaria posea al menos un segmento inhibidor de la activación de la proteasa NS3 de un virus de la familia Flaviviridae, y un segmento penetrador de células, capaz de inhibir o atenuar la infección por el virus, y con compuestos farmacéuticos que contienen los péptidos quiméricos para la prevención y/o tratamiento de las infecciones causadas por virus de la familia Flaviviridae.
CU20060207A 2006-10-30 2006-10-30 Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae CU23630A1 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CU20060207A CU23630A1 (es) 2006-10-30 2006-10-30 Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
KR1020097010930A KR101449494B1 (ko) 2006-10-30 2007-10-30 플라비바이러스 과의 바이러스에 대해 항바이러스 특성을 갖는 키메르 펩티드 분자
RU2009120596/10A RU2451026C2 (ru) 2006-10-30 2007-10-30 Химерные пептидные молекулы с противовирусными свойствами в отношении вирусов семейства flaviviridae
CN2007800466743A CN101588818B (zh) 2006-10-30 2007-10-30 具有针对黄病毒科病毒的抗病毒性质的嵌合肽分子
US12/513,085 US8674063B2 (en) 2006-10-30 2007-10-30 Chimerical peptidic molecules with antiviral properties against the viruses of the Flaviviridae family
CA2668045A CA2668045C (en) 2006-10-30 2007-10-30 Peptide chimeric molecules having antiviral properties against viruses of the flaviviridae family
ES07817384T ES2392106T3 (es) 2006-10-30 2007-10-30 Moléculas peptídicas quiméricas con propiedades antivíricas contra los virus de la familia Flaviviridae
AU2007315485A AU2007315485A1 (en) 2006-10-30 2007-10-30 Peptide chimeric molecules having antiviral properties against viruses of the flaviviridae family
PCT/CU2007/000020 WO2008052490A2 (es) 2006-10-30 2007-10-30 Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae.
EP07817384A EP2085098B1 (en) 2006-10-30 2007-10-30 Peptide chimeric molecules having antiviral properties against viruses of the flaviviridae family
MX2009004761A MX2009004761A (es) 2006-10-30 2007-10-30 Moleculas peptidicas quimericas con propiedades antivirales contra los virus de la familia flaviviridae.
JP2009534979A JP5253405B2 (ja) 2006-10-30 2007-10-30 フラビウイルス科ファミリーのウイルスに対して抗ウイルス特性を有するキメラペプチド分子
ARP070104814A AR063725A1 (es) 2006-10-30 2007-10-30 Moleculas peptidicas quimericas con propiedades antivirales contra los virus de la familia flaviviridae
BRPI0718097-7A BRPI0718097A2 (pt) 2006-10-30 2007-10-30 Peptídeos quiméricos e composição farmacêutica.
ZA200903318A ZA200903318B (en) 2006-10-30 2009-05-13 Peptide chimeric molecules having antiviral properties against viruses of the flaviviridae family

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060207A CU23630A1 (es) 2006-10-30 2006-10-30 Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae

Publications (1)

Publication Number Publication Date
CU23630A1 true CU23630A1 (es) 2011-02-24

Family

ID=39344620

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20060207A CU23630A1 (es) 2006-10-30 2006-10-30 Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae

Country Status (15)

Country Link
US (1) US8674063B2 (es)
EP (1) EP2085098B1 (es)
JP (1) JP5253405B2 (es)
KR (1) KR101449494B1 (es)
CN (1) CN101588818B (es)
AR (1) AR063725A1 (es)
AU (1) AU2007315485A1 (es)
BR (1) BRPI0718097A2 (es)
CA (1) CA2668045C (es)
CU (1) CU23630A1 (es)
ES (1) ES2392106T3 (es)
MX (1) MX2009004761A (es)
RU (1) RU2451026C2 (es)
WO (1) WO2008052490A2 (es)
ZA (1) ZA200903318B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133112A1 (en) * 2010-04-20 2011-10-27 National University Of Singapore Cell penetrating peptide derived from the premembrane protein of flavivirus
US9321847B2 (en) 2010-09-20 2016-04-26 Ramot At Tel Aviv University Ltd. Activatable toxin complexes comprising a cleavable inhibitory peptide
JP2014505064A (ja) * 2011-01-26 2014-02-27 セニックス バイオサイエンス ゲーエムベーハー 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート
HUE040564T2 (hu) 2011-06-24 2019-03-28 Nono Inc Kombinációs ischemia terápia
US9241970B2 (en) * 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
CU20140026A7 (es) * 2014-03-03 2015-11-27 Ct De Ingeniería Genética Y Biotecnología Biocubafarma Péptidos horquilla beta con propiedades antivirales contra el virus dengue
CN106414504B (zh) * 2014-04-04 2020-12-18 马尔科·费利焦尼 用于治疗由谷氨酸兴奋性毒性引起的疾病的细胞可渗透肽系统
CN111000981B (zh) * 2019-12-12 2021-08-13 中山大学 抗病毒蛋白C19orf66在靶向寨卡病毒非结构蛋白NS3抗病毒药物中的应用
CN113876755A (zh) * 2021-09-23 2022-01-04 天津国际生物医药联合研究院 阿伐麦布在抗圣路易斯脑炎病毒感染中的潜在应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22302A1 (es) 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
ATE443143T1 (de) 1991-09-19 2009-10-15 Us Health Chimäre und/oder wachstumgehemmte flaviviren
ATE227584T1 (de) 1995-05-24 2002-11-15 Hawaii Biotech Group Untereinheitsimpfstoff gegen flavivirus infektion
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
EP0907659A1 (en) * 1996-05-10 1999-04-14 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
CU22666A1 (es) 1996-11-25 2001-04-27 Inst De Medicina Tropical Pedro Kouri Procedimiento para la expresión de genes de los virus del dengue en la levadura pichia pastoris, adns recombinantes y microorganismos transformados
CU22683A1 (es) 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
IL134232A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides
DE69833002T2 (de) 1997-10-08 2006-08-24 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Chimärer impfstoff gegen das zeckenenzephalitis virus
CA2371032A1 (en) 1999-04-30 2000-11-09 Chiron Corporation Neisseria genomic sequences and methods of their use
US7034109B2 (en) * 2000-10-13 2006-04-25 Christophe Bonny Intracellular delivery of biological effectors
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
AU2003239932A1 (en) 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
WO2004052293A2 (en) 2002-12-11 2004-06-24 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
EP1454988A1 (en) 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious flavivirus pseudo-particles containing functional prM-E envelope proteins
WO2005002501A2 (en) 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
AR052195A1 (es) 2005-01-19 2007-03-07 Vaxinnate Corp Composiciones de patrones moleculares asociados a patogenos en metodos de uso
CA2508266A1 (fr) * 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
CU23632A1 (es) * 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.

Also Published As

Publication number Publication date
JP2010526022A (ja) 2010-07-29
MX2009004761A (es) 2009-06-05
EP2085098B1 (en) 2012-07-25
AU2007315485A1 (en) 2008-05-08
ES2392106T3 (es) 2012-12-04
CA2668045C (en) 2014-03-25
KR20090077077A (ko) 2009-07-14
WO2008052490A2 (es) 2008-05-08
BRPI0718097A2 (pt) 2013-11-05
CA2668045A1 (en) 2008-05-08
EP2085098A2 (en) 2009-08-05
US20100273702A1 (en) 2010-10-28
US8674063B2 (en) 2014-03-18
CN101588818B (zh) 2013-05-08
JP5253405B2 (ja) 2013-07-31
RU2451026C2 (ru) 2012-05-20
CN101588818A (zh) 2009-11-25
KR101449494B1 (ko) 2014-10-13
AR063725A1 (es) 2009-02-11
RU2009120596A (ru) 2010-12-10
ZA200903318B (en) 2010-07-28
WO2008052490A3 (es) 2008-11-06

Similar Documents

Publication Publication Date Title
CU23630A1 (es) Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
CU24046B1 (es) Compuestos peptídicos que inhiben el virus de la hepatitis c
CL2011000145A1 (es) Compuesto macrociclico derivado de quinoxalina y sus sales; inhibidor de la proteasa ns3 del virus de la hepatitis c(hcv); composicion farmaceutica que lo comprende; y uso en la prevencion o el tratamiento de una infeccion por hcv.
NI200900069A (es) Inhibidores de la proteasa ns3 del hcv
EA200901101A1 (ru) Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс
GT200600317A (es) Inhibidores de la proteasa ns3 del vhc
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
CO6440581A2 (es) Inhibidores del virus de la hepatitis c
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
CL2012001230A1 (es) Compuestos derivados de biciclos, inhibidores de la proteina ns5a; composicion farmaceutica que los comprende; uso en el tratamiento de la hepatitis c.
CR11310A (es) Espiro-Pirrolidinas y su uso contra infeccion por el virus de Hepatitis C (HCV) y por el virus de Inmunodeficiencia Humana (VIH)
DE602007006796D1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
CL2011002453A1 (es) Compuestos derivados de diazol u oxazol-pirrol o pirrolciclopropil condensados sustituidos, inhibidores de la función de la proteína ns5a codificada por el virus de la hepatitis c (vhc); composición farmacéutica; y su uso para el tratamiento de una infección por vhc.
PE20110343A1 (es) Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina
CL2012000919A1 (es) Composicion que comprende un compuesto derivado de metoxicarbonil-amino-metilbutanoil-pirrolidinil-imidazol de formula i, inhibidor especifico de ns5a de hcv, y un compuesto derivado de oxo-pirrolidin-quinoleina de formula ii, inhibidor de proteasa ns3 de hcv; y uso en el tratamiento de la hepatitis c.
ECSP14013315A (es) Inhibidores de aplicación viral
CL2013000727A1 (es) Compuestos derivados de nucleosidos de imidazo[1,2-f][1,2,4]triazinilo; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion por virus flaviviridae, particularmente infecciones por el virus de la hepatitis c.
CL2012000573A1 (es) Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv.
AR084393A1 (es) Metodos para tratar el virus de la hepatitis c, composicion, uso, combinacion, kit y uno o mas compuestos anti vhc
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
GT200600262A (es) Uso de la sangliferina en el hcv (virus de la hepatitis "c")
CL2008000959A1 (es) Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c.
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
BR112013020042A2 (pt) inibidores de vírus da hepatite c
DOP2014000034A (es) Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv)